Sir,
An acute or hyper-acute rejection in any solid organ transplant is due to the presence of preformed anti-HLA antibodies. [1] These antibodies can be identified with cell-based assays; Complement-dependent Lympho-Cytotoxicity Crossmatch (CDCXM) and Flow Cytometry crossmatch (FCXM) and bead-based assays; Panel Reacting Antibodies (PRA) and Single Antigen Bead (SAB). [2] Using cell-based and bead-based assays in an algorithmic manner combines relative merits of each assay to our advantage and allows better interpretation of results. Routinely, in a pre-renal transplant work-up, commonest scenarios are where cell-based crossmatch and SAB are concordant, either negative or positive. We present a case that belongs to a third scenario, an unusual presentation, where CDCXM and FCXM were negative; SAB was positive and virtual crossmatch revealed Donor Specific Antibody (DSA).
A 25-year-old male patient suffering from end-stage renal disease was referred to our laboratory by the nephrologist for pre-transplant workup with his wife as prospective donor. As per the institutional protocol, low resolution HLA typing for class I (A and B) and class II (DR) antigens {polymerase chain reaction-sequence specific oligonucleotide probes (PCR-SSOP)} was performed for assessing relationship as a pre-requisite according to The Human Organ Transplant Act, India, 1994 and its amendments. [3] Anti-HLA antibody detection was negative by CDCXM and FCXM. CDCXM was performed using the standard National Institute of Health (NIH) technique and FCXM was performed for T-cell and B-cell on BD FACSVerse™ Flow cytometer (San Jose, CA, USA). Since the patient had history of blood transfusion, PRA was performed using Flow PRA Class I & II Screening Test kit (One Lambda, Inc., CA, USA) and it was found positive. As this scenario presented a discrepancy between cell-based and bead-based methods, repeat testing were done to rule out any technical errors. However, results remained the same.
Decision was taken to perform SAB assay (LIFECODES LSA™ Kit, Immucor Transplant Diagnostics Inc., USA) on Luminex platform. SAB assay was positive for class I antibodies and negative for class II antibodies. Antibodies were identified against HLA-A*24:03 (MFI-11531) and HLA-A*24:02 (MFI-5252). Low resolution typing identified donor HLA-A allele as A*24 only. Therefore, high resolution typing for donor HLA-A locus was also done to identify complete antigen. High resolution typing revealed HLA-A*24:03 in donor and confirmed the presence of DSA.
To further understand and resolve this uncommon discrepancy between cell-based crossmatch and SAB, literature was reviewed. [4] Of all the possible mentioned reasons for such discordance, performing tests to negate pro-zone and post-zone phenomenon was undertaken and FCXM was repeated with dilutions of recipient's serum and donor's cells (dilutions 1:2 to 1:8). FCXM was found to be positive for T cells (median channel shift was 59; cut-off ≥26) and negative for B cells (median channel shift was 98; cut-off ≥110) with donor cells in 1:2 dilutions [ Table 1 and Figure 1 ]. This positive result for T-cell FCXM corroborated with SAB results and resolved the discrepancy.
All tests, CDCXM, FCXM, PRA, and SAB, are used to detect the presence of donor-specific anti-HLA antibodies (DSA) in the recipient and in most of the cases, results of all tests are in concordance. However, rarely there can be discordance. Literature review identified following reasons for discordance: Pro-zone/Post-zone effect, stability of antigens, antibody against denatured antigens v/s native antigen and allelic expression on the donor cell surface.
In the present case, post-zone phenomenon was responsible for the discordance between results of cell-based and bead-based assays. Excess of antigen inhibits lattice formation and subsequent agglutination between antigen-antibody may not occur, which can give false-negative results. Diluting the donor cells or increasing the serum-to-cell ratio can solve the problem.
The case also highlights the importance of performing cell-based and bead-based assay, in an algorithmic manner, in a pre-transplant work-up to rule-out any donor specific antibodies, especially if the recipient has history of any sensitizing event. It can be concluded that in these cases where cell-based assays results are discordant with the SAB assay results, post-zone effect should also be considered to confirm or rule out DSA.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed. 
Pre-transplant Compatibility Tests in Kidney Transplants: Case Report on Significance of Epitope-based Analysis in Donor Selection
Sir, Detection of alloantibodies is one of the main objectives of compatibility work-up before transplantation. One of the common strategies employed in India is to perform complement-dependent cytotoxicity cross-match (CDC) and flow cytometry-based cross-match (FCXM) tests. [1] If either or both of these tests are positive, Luminex-based single antigen bead (SAB) assay is performed to identify specific antibodies. These antibodies are then matched with human-leukocyte antigens (HLA) of prospective donor to determine donor-specific antibody (DSA), called virtual cross-match. [2] Routinely matching is done at antigen level; not at epitope level. Antibodies positive at antigen level can be negative at epitope level and vice versa. [3, 4] Epitopes are configurations of polymorphic amino acid residues that are recognized by B cells, and antibodies reactive with these epitopes lead to rejection and/or premature allograft loss. we report our experience of two cases having history of sensitization, where class II (DPA1) antibody was ruled out as a DSA, only because of epitope analysis. Since this has a clinical implication of deciding the prospective kidney donor, epitope analysis may be used routinely in all SAB test interpretation.
Recipient serum samples were collected for Luminex SAB assay (LIFECODES LSA™ Kit Immucor Transplant Diagnostics, Inc. USA.) to identify the DSA. Luminex software (Match IT antibody) was used for antigen-based analysis (cut-off; BCM ≥1000/positive by machine) and Epitope-based analysis was done with the help of freely available online software 'HLA Matchmaker' (http://www. epitopes.net). Table 1 , we presented two cases where both the patients and prospective donors were females, having history of sensitization. All three tests (CDCXM, FCXM, and SAB) were performed for pre-transplant workup. In the first case, CDC cross-match was negative and FCXM was positive for both T and B cells and in the second case CDC and B cell FCXM were negative; T cell FCXM was positive. DSA was identified in class I and class II in both cases. DSA allele matching at antigen and epitope level was performed. In both cases, epitope analysis revealed that antibody against DP locus was not DSA.
As described in
Both these patients had significant DSA in class I (case I -B*44:03 and case II -B*44:02) and class II (case I-DRB1*10:01; DPA1*02:01-DPB1*04:01 and case II DPA1*01:03-DPB1*06:01). Case 2 underwent desensitization by therapeutic plasma exchange (TPE) followed by retesting for median fluorescence intensity MFI. The patient (case 2) underwent successful renal transplant once MFI below 500 [5] was achieved. However, what we would like the readers of journal know that if we had considered antigen-based analysis only and if these Class II (case I-DPA1*02:01-DPB1*04:01 and case II; DPA1*01:03-DPB1*06:01) were the only antibodies present in the recipient; it would have led to donor deferral. The epitope-based analysis resolved that DPA1*02:01-DPB1*04:01 in case I and DPA1*01:03-DPB1*06:01 in case II were not DSA and these patients could have undergone successful transplant even without TPE. India is a predominantly live-related transplant setting where only close relatives can be organ donors as per Transplantation of Human Organs and Tissues Act (THOTA) 2014. [6] To have a willing donor in the family, by itself is difficult and any unnecessary deferral would be catastrophic for the recipient and her/his family. It is in this light, that epitope-based analysis assumes even greater significance.
